ARTICLE | Company News
FDA accepts sorafenib NDA
September 15, 2005 1:30 AM UTC
FDA accepted for filing and granted Priority Review to an NDA for sorafenib ( BAY 43-9006) from Onyx (ONXX) and partner Bayer (FSE:BAYG; BAY) to treat advanced renal cell carcinoma (RCC). Submission o...